← 返回

用于控制植入式细胞疗法的新兴哺乳动物基因开关

英文原题:Emerging mammalian gene switches for controlling implantable cell therapies.

查看英文原题

Emerging mammalian gene switches for controlling implantable cell therapies.

PubMed 2021/06/30(内容时间) Curr Opin Chem Biol Q1 · IF 7.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

工程化细胞疗法已成为现代医学的一种新范式,目前已有若干工程化T细胞疗法获批用于治疗血液系统恶性肿瘤,还有更多疗法处于临床开发阶段。过去二十年合成生物学的巨大进步使我们能够为细胞编程复杂的感知-响应模块,从而有效控制治疗功能。在这篇综述中,我们重点介绍哺乳动物合成基因开关的最新进展,聚焦于为治疗应用而设计的装置。尽管已经开发出许多响应内源性或外源性分子信号的基因开关,但研究重点正转向通过用无痕物理信号(如光、电信号、磁场、热或超声)刺激植入的工程化细胞,实现治疗效应分子的远程控制生产。

展开英文摘要原文

Engineered cell-based therapies have emerged as a new paradigm in modern medicine, with several engineered T cell therapies currently approved to treat blood cancers and many more in clinical development. Tremendous progress in synthetic biology over the past two decades has allowed us to program cells with sophisticated sense-and-response modules that can effectively control therapeutic functions.

In this review, we highlight recent advances in mammalian synthetic gene switches, focusing on devices designed for therapeutic applications. Although many gene switches responding to endogenous or exogenous molecular signals have been developed, the focus is shifting towards achieving remote-controlled production of therapeutic effectors by stimulating implanted engineered cells with traceless physical signals, such as light, electrical signals, magnetic fields, heat or ultrasound.

论文信息

作者
Madderson O、Teixeira AP、Fussenegger M
第一作者单位
ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland.Ethiopia
通讯作者单位
ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland; University of Basel, Faculty of Life Science, Basel, Switzerland. Electronic address: fussenegger@bsse.ethz.ch.Ethiopia
文献类型
非美国政府资助研究 · 综述
期刊
Current opinion in chemical biology2021 Oct
原文标识
PubMed 34216875 · DOI 10.1016/j.cbpa.2021.05.012